Global ELISpot and FluoroSpot Assay Market, By Product; By Assay Type; By Source; By Disease; By Application; By End User; By Region, Trend Analysis, Competitive Landscape & Forecast, 2019-2030

Description

Global ELISpot and FluoroSpot Assay Market Size Expands at CAGR of 7.6% to Reach USD 479.5 Million by 2030

Global ELISpot and FluoroSpot Assay Market is flourishing because of the growing demand for sensitive and specific assays and advancements in biotechnology.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global ELISpot and FluoroSpot Assay Market size at USD 289.80 million in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global ELISpot and FluoroSpot Assay Market size to expand at a CAGR of 7.60% reaching a value of USD 479.50 million by 2030. Several factors contribute to the market growth, including the rising prevalence of chronic diseases, the emergence of new infectious diseases, and the growing demand for vaccines to prevent infectious diseases. Companies' technological advancements are also expected to drive Global ELISpot and FluoroSpot Assays Market over the forecast period.

Opportunity - Increasing Prevalence of Infectious Diseases

The rising prevalence of various infectious diseases, such as malaria, leishmaniasis, and HIV-AIDS, globally is directly propelling the demand for ELISpot and fluoroSport assays. Cancer also covers a significant market share owing to the growing burden of cancer worldwide and the rising need for its early detection.

Impact of Escalating Geopolitical Tensions on Global ELISpot and FluoroSpot Assay Market

Escalating geopolitical tensions could negatively impact the growth of Global ELISpot and FluoroSpot Assay Market. Increased tensions may result in trade restrictions or sanctions, limiting the supply of reagents and equipment required for these experiments. It might reduce investments in R&D programs and delay new product launches. Geopolitical instability might inhibit investment in biotech businesses, resulting in less financing for new assay development, thereby slowing improvements in ELISpot and FluoroSpot technologies. Governments may place more stern controls on biological goods and research, affecting the approval procedure and market entrance of novel assays. In areas of war or instability, there may be a greater emphasis on healthcare and diagnostics, which might increase demand for assays to detect infectious illnesses or immunological responses.

Diagnostics Application Segment Holds Largest Market Share

The diagnostic applications category accounts for the majority of the market and is anticipated to grow at a rapid rate over the course of the forecast period. The development of sophisticated kits for the early identification of illnesses and the increased prevalence of numerous infectious diseases are driving expansion in the diagnostic segment. However, the market for research applications is also growing significantly, particularly in light of the COVID-19 pandemic. Other major application segments of Global ELISpot and FluoroSpot Assay Market include research applications.

Asia Pacific to Grow at Fastest CAGR in Global Market

The Asia Pacific region is projected to record growth at the fastest CAGR over the forecast period. The population of emerging economies is much higher as compared to the developed countries, due to which the percentage of population suffering from various chronic and infectious diseases is also high. As a result, the ELISpot and FluoroSpot Assays Market is gaining significant traction in the Asia Pacific region. Moreover, China is projected to remain among the fastest-growing markets in the APAC region.

Competitive Landscape

Global ELISpot and FluoroSpot Assay Market is intensely competitive, as a number of companies are competing to gain a significant market share. Key players in the market include Oxford Immunotec USA, Inc., BD, R&D Systems, Inc., Mabtech, Thermo Fisher Scientific, Covalab, Inc., Autoimmun Diagnostika GmbH, Abcam Limited, Labcorp Drug Development, Cellular Technology Limited, U-CyTech, Bio-Techne, and Mikrogen GmbH.

To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and Global ELISpot and FluoroSpot Assay Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global ELISpot and FluoroSpot Assay Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Product Code: BWC24713

1. Research Framework

1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation

2. Executive Summary

3. Global ELISpot and FluoroSpot Assay Market Insights

3.1. Industry Value Chain Analysis
- 3.1.1. DROC Analysis
- 3.1.2. Growth Drivers
  - 3.1.2.1. Growing Demand for Sensitive and Specific Assays
  - 3.1.2.2. Advancements in Biotechnology
  - 3.1.2.3. Increasing Prevalence of Chronic Diseases
  - 3.1.2.4. Growing Research Activities in Immunology
- 3.1.3. Restraints
  - 3.1.3.1. High Costs
  - 3.1.3.2. Technical Complexity
  - 3.1.3.3. Limited Availability of Reagents
- 3.1.4. Opportunities
  - 3.1.4.1. Expanding Applications
  - 3.1.4.2. Emerging Markets
  - 3.1.4.3. Integration with Other Technologies
- 3.1.5. Challenges
  - 3.1.5.1. Competition from Alternative Technologies
  - 3.1.5.2. Regulatory Hurdles
  - 3.1.5.3. Ethical Considerations
3.2. Technological Advancements/Recent Developments
3.3. Regulatory Framework
3.4. Porter's Five Forces Analysis
- 3.4.1. Bargaining Power of Suppliers
- 3.4.2. Bargaining Power of Buyers
- 3.4.3. Threat of New Entrants
- 3.4.4. Threat of Substitutes
- 3.4.5. Intensity of Rivalry

4. Global ELISpot and FluoroSpot Assay Market: Marketing Strategies

5. Global ELISpot and FluoroSpot Assay Market Overview

5.1. Market Energy Capacity & Forecast, 2019-2030
- 5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
- 5.2.1. By Product
  - 5.2.1.1. Assay Kits
  - 5.2.1.1.1. T Cell assay
  - 5.2.1.1.2. B Cell assay
  - 5.2.1.2. Analysers
  - 5.2.1.3. Supplementary or Ancillary Products
- 5.2.2. By Assay Type
  - 5.2.2.1. ELISpot Assay Kits
  - 5.2.2.2. FluoroSpot Assay Kits
- 5.2.3. By Source
  - 5.2.3.1. Human
  - 5.2.3.2. Mouse
  - 5.2.3.3. Monkey
  - 5.2.3.4. Others
- 5.2.4. By Diseases
  - 5.2.4.1. Infectious Diseases
  - 5.2.4.2. Cancer
  - 5.2.4.3. Autoimmune Diseases
  - 5.2.4.4. Allergy
  - 5.2.4.5. Others
- 5.2.5. By Application
  - 5.2.5.1. Diagnostic Applications
  - 5.2.5.2. Research Applications
- 5.2.6. By End User
  - 5.2.6.1. Hospitals & Clinical Laboratories
  - 5.2.6.2. Research Institutes
  - 5.2.6.3. Biopharmaceutical Companies
  - 5.2.6.4. Others
- 5.2.7. By Region
  - 5.2.7.1. North America
  - 5.2.7.2. Europe
  - 5.2.7.3. Asia Pacific (APAC)
  - 5.2.7.4. Latin America (LATAM)
  - 5.2.7.5. Middle East and Africa (MEA)

6. North America ELISpot and FluoroSpot Assay Market

6.1. Market Energy Capacity & Forecast, 2019-2030
- 6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Assay Type
- 6.2.3. By Source
- 6.2.4. By Diseases
- 6.2.5. By Application
- 6.2.6. By End User
- 6.2.7. By Country
  - 6.2.7.1. United States
  - 6.2.7.1.1. By Product
  - 6.2.7.1.2. By Assay Type
  - 6.2.7.1.3. By Source
  - 6.2.7.1.4. By Diseases
  - 6.2.7.1.5. By Application
  - 6.2.7.1.6. By End User
  - 6.2.7.2. Canada
  - 6.2.7.2.1. By Product
  - 6.2.7.2.2. By Assay Type
  - 6.2.7.2.3. By Source
  - 6.2.7.2.4. By Diseases
  - 6.2.7.2.5. By Application
  - 6.2.7.2.6. By End User

7. Europe ELISpot and FluoroSpot Assay Market

7.1. Market Energy Capacity & Forecast, 2019-2030
- 7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Assay Type
- 7.2.3. By Source
- 7.2.4. By Diseases
- 7.2.5. By Application
- 7.2.6. By End User
- 7.2.7. By Country
  - 7.2.7.1. Germany
  - 7.2.7.1.1. By Product
  - 7.2.7.1.2. By Assay Type
  - 7.2.7.1.3. By Source
  - 7.2.7.1.4. By Diseases
  - 7.2.7.1.5. By Application
  - 7.2.7.1.6. By End User
  - 7.2.7.2. United Kingdom
  - 7.2.7.2.1. By Product
  - 7.2.7.2.2. By Assay Type
  - 7.2.7.2.3. By Source
  - 7.2.7.2.4. By Diseases
  - 7.2.7.2.5. By Application
  - 7.2.7.2.6. By End User
  - 7.2.7.3. Italy
  - 7.2.7.3.1. By Product
  - 7.2.7.3.2. By Assay Type
  - 7.2.7.3.3. By Source
  - 7.2.7.3.4. By Diseases
  - 7.2.7.3.5. By Application
  - 7.2.7.3.6. By End User
  - 7.2.7.4. France
  - 7.2.7.4.1. By Product
  - 7.2.7.4.2. By Assay Type
  - 7.2.7.4.3. By Source
  - 7.2.7.4.4. By Diseases
  - 7.2.7.4.5. By Application
  - 7.2.7.4.6. By End User
  - 7.2.7.5. Spain
  - 7.2.7.5.1. By Product
  - 7.2.7.5.2. By Assay Type
  - 7.2.7.5.3. By Source
  - 7.2.7.5.4. By Diseases
  - 7.2.7.5.5. By Application
  - 7.2.7.5.6. By End User
  - 7.2.7.6. Belgium
  - 7.2.7.6.1. By Product
  - 7.2.7.6.2. By Assay Type
  - 7.2.7.6.3. By Source
  - 7.2.7.6.4. By Diseases
  - 7.2.7.6.5. By Application
  - 7.2.7.6.6. By End User
  - 7.2.7.7. Russia
  - 7.2.7.7.1. By Product
  - 7.2.7.7.2. By Assay Type
  - 7.2.7.7.3. By Source
  - 7.2.7.7.4. By Diseases
  - 7.2.7.7.5. By Application
  - 7.2.7.7.6. By End User
  - 7.2.7.8. The Netherlands
  - 7.2.7.8.1. By Product
  - 7.2.7.8.2. By Assay Type
  - 7.2.7.8.3. By Source
  - 7.2.7.8.4. By Diseases
  - 7.2.7.8.5. By Application
  - 7.2.7.8.6. By End User
  - 7.2.7.9. Rest of Europe
  - 7.2.7.9.1. By Product
  - 7.2.7.9.2. By Assay Type
  - 7.2.7.9.3. By Source
  - 7.2.7.9.4. By Diseases
  - 7.2.7.9.5. By Application
  - 7.2.7.9.6. By End User

8. Asia Pacific ELISpot and FluoroSpot Assay Market

8.1. Market Energy Capacity & Forecast, 2019-2030
- 8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Assay Type
- 8.2.3. By Source
- 8.2.4. By Diseases
- 8.2.5. By Application
- 8.2.6. By End User
- 8.2.7. By Country
  - 8.2.7.1. China
  - 8.2.7.1.1. By Product
  - 8.2.7.1.2. By Assay Type
  - 8.2.7.1.3. By Source
  - 8.2.7.1.4. By Diseases
  - 8.2.7.1.5. By Application
  - 8.2.7.1.6. By End User
  - 8.2.7.2. India
  - 8.2.7.2.1. By Product
  - 8.2.7.2.2. By Assay Type
  - 8.2.7.2.3. By Source
  - 8.2.7.2.4. By Diseases
  - 8.2.7.2.5. By Application
  - 8.2.7.2.6. By End User
  - 8.2.7.3. Japan
  - 8.2.7.3.1. By Product
  - 8.2.7.3.2. By Assay Type
  - 8.2.7.3.3. By Source
  - 8.2.7.3.4. By Diseases
  - 8.2.7.3.5. By Application
  - 8.2.7.3.6. By End User
  - 8.2.7.4. South Korea
  - 8.2.7.4.1. By Product
  - 8.2.7.4.2. By Assay Type
  - 8.2.7.4.3. By Source
  - 8.2.7.4.4. By Diseases
  - 8.2.7.4.5. By Application
  - 8.2.7.4.6. By End User
  - 8.2.7.5. Australia & New Zealand
  - 8.2.7.5.1. By Product
  - 8.2.7.5.2. By Assay Type
  - 8.2.7.5.3. By Source
  - 8.2.7.5.4. By Diseases
  - 8.2.7.5.5. By Application
  - 8.2.7.5.6. By End User
  - 8.2.7.6. Indonesia
  - 8.2.7.6.1. By Product
  - 8.2.7.6.2. By Assay Type
  - 8.2.7.6.3. By Source
  - 8.2.7.6.4. By Diseases
  - 8.2.7.6.5. By Application
  - 8.2.7.6.6. By End User
  - 8.2.7.7. Malaysia
  - 8.2.7.7.1. By Product
  - 8.2.7.7.2. By Assay Type
  - 8.2.7.7.3. By Source
  - 8.2.7.7.4. By Diseases
  - 8.2.7.7.5. By Application
  - 8.2.7.7.6. By End User
  - 8.2.7.8. Singapore
  - 8.2.7.8.1. By Product
  - 8.2.7.8.2. By Assay Type
  - 8.2.7.8.3. By Source
  - 8.2.7.8.4. By Diseases
  - 8.2.7.8.5. By Application
  - 8.2.7.8.6. By End User
  - 8.2.7.9. Vietnam
  - 8.2.7.9.1. By Product
  - 8.2.7.9.2. By Assay Type
  - 8.2.7.9.3. By Source
  - 8.2.7.9.4. By Diseases
  - 8.2.7.9.5. By Application
  - 8.2.7.9.6. By End User
  - 8.2.7.10. Rest of APAC
  - 8.2.7.10.1. By Product
  - 8.2.7.10.2. By Assay Type
  - 8.2.7.10.3. By Source
  - 8.2.7.10.4. By Diseases
  - 8.2.7.10.5. By Application
  - 8.2.7.10.6. By End User

9. Latin America ELISpot and FluoroSpot Assay Market

9.1. Market Energy Capacity & Forecast, 2019-2030
- 9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Assay Type
- 9.2.3. By Source
- 9.2.4. By Diseases
- 9.2.5. By Application
- 9.2.6. By End User
- 9.2.7. By Country
  - 9.2.7.1. Brazil
  - 9.2.7.1.1. By Product
  - 9.2.7.1.2. By Assay Type
  - 9.2.7.1.3. By Source
  - 9.2.7.1.4. By Diseases
  - 9.2.7.1.5. By Application
  - 9.2.7.1.6. By End User
  - 9.2.7.2. Mexico
  - 9.2.7.2.1. By Product
  - 9.2.7.2.2. By Assay Type
  - 9.2.7.2.3. By Source
  - 9.2.7.2.4. By Diseases
  - 9.2.7.2.5. By Application
  - 9.2.7.2.6. By End User
  - 9.2.7.3. Argentina
  - 9.2.7.3.1. By Product
  - 9.2.7.3.2. By Assay Type
  - 9.2.7.3.3. By Source
  - 9.2.7.3.4. By Diseases
  - 9.2.7.3.5. By Application
  - 9.2.7.3.6. By End User
  - 9.2.7.4. Peru
  - 9.2.7.4.1. By Product
  - 9.2.7.4.2. By Assay Type
  - 9.2.7.4.3. By Source
  - 9.2.7.4.4. By Diseases
  - 9.2.7.4.5. By Application
  - 9.2.7.4.6. By End User
  - 9.2.7.5. Rest of LATAM
  - 9.2.7.5.1. By Product
  - 9.2.7.5.2. By Assay Type
  - 9.2.7.5.3. By Source
  - 9.2.7.5.4. By Diseases
  - 9.2.7.5.5. By Application
  - 9.2.7.5.6. By End User

10. Middle East & Africa ELISpot and FluoroSpot Assay Market

10.1. Market Energy Capacity & Forecast, 2019-2030
- 10.1.1. By Value (USD Million)
10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Assay Type
- 10.2.3. By Source
- 10.2.4. By Diseases
- 10.2.5. By Application
- 10.2.6. By End User
- 10.2.7. By Country
  - 10.2.7.1. Saudi Arabia
  - 10.2.7.1.1. By Product
  - 10.2.7.1.2. By Assay Type
  - 10.2.7.1.3. By Source
  - 10.2.7.1.4. By Diseases
  - 10.2.7.1.5. By Application
  - 10.2.7.1.6. By End User
  - 10.2.7.2. UAE
  - 10.2.7.2.1. By Product
  - 10.2.7.2.2. By Assay Type
  - 10.2.7.2.3. By Source
  - 10.2.7.2.4. By Diseases
  - 10.2.7.2.5. By Application
  - 10.2.7.2.6. By End User
  - 10.2.7.3. Qatar
  - 10.2.7.3.1. By Product
  - 10.2.7.3.2. By Assay Type
  - 10.2.7.3.3. By Source
  - 10.2.7.3.4. By Diseases
  - 10.2.7.3.5. By Application
  - 10.2.7.3.6. By End User
  - 10.2.7.4. Kuwait
  - 10.2.7.4.1. By Product
  - 10.2.7.4.2. By Assay Type
  - 10.2.7.4.3. By Source
  - 10.2.7.4.4. By Diseases
  - 10.2.7.4.5. By Application
  - 10.2.7.4.6. By End User
  - 10.2.7.5. South Africa
  - 10.2.7.5.1. By Product
  - 10.2.7.5.2. By Assay Type
  - 10.2.7.5.3. By Source
  - 10.2.7.5.4. By Diseases
  - 10.2.7.5.5. By Application
  - 10.2.7.5.6. By End User
  - 10.2.7.6. Nigeria
  - 10.2.7.6.1. By Product
  - 10.2.7.6.2. By Assay Type
  - 10.2.7.6.3. By Source
  - 10.2.7.6.4. By Diseases
  - 10.2.7.6.5. By Application
  - 10.2.7.6.6. By End User
  - 10.2.7.7. Algeria
  - 10.2.7.7.1. By Product
  - 10.2.7.7.2. By Assay Type
  - 10.2.7.7.3. By Source
  - 10.2.7.7.4. By Diseases
  - 10.2.7.7.5. By Application
  - 10.2.7.7.6. By End User
  - 10.2.7.8. Rest of MEA
  - 10.2.7.8.1. By Product
  - 10.2.7.8.2. By Assay Type
  - 10.2.7.8.3. By Source
  - 10.2.7.8.4. By Diseases
  - 10.2.7.8.5. By Application
  - 10.2.7.8.6. By End User

11. Competitive Landscape

11.1. List of Key Players and Their Offerings
11.2. Global ELISpot and FluoroSpot Assay Company Market Share Analysis, 2023
11.3. Competitive Benchmarking, By Operating Parameters
11.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

12. Impact of Escalating Geopolitical Tensions on Global ELISpot and FluoroSpot Assay Market

13. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

13.1. Oxford Immunotec USA, Inc.
13.2. BD
13.3. R&D Systems, Inc.
13.4. Mabtech
13.5. Thermo Fisher Scientific
13.6. Covalab, Inc.
13.7. Autoimmun Diagnostika GmbH
13.8. Abcam Limited
13.9. Labcorp Drug Development
13.10. Cellular Technology Limited
13.11. U-CyTech
13.12. Bio-Techne
13.13. Mikrogen GmbH
13.14. Other Prominent Players

14. Key Strategic Recommendations

15. Research Methodology

15.1. Qualitative Research
- 15.1.1. Primary & Secondary Research
15.2. Quantitative Research
15.3. Market Breakdown & Data Triangulation
- 15.3.1. Secondary Research
- 15.3.2. Primary Research
15.4. Breakdown of Primary Research Respondents, By Region
15.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable